Shire’s SHP647 Shows Promise as Potential Ulcerative Colitis Treatment, Study Finds

Shire’s SHP647 Shows Promise as Potential Ulcerative Colitis Treatment, Study Finds
Treatment with SHP647 (also known as PF-00547659) significantly decreased remission rates in a Phase 2 clinical trial of patients with ulcerative colitis, a type of inflammatory bowel disease (IBD). The drug is licensed by Shire and was originally designed by Pfizer. Results of this trial were published in The Lancet with the title, “Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.” The two major types of IBD are ulcerative colitis and Crohn’s disease, which usually cause symptoms such as pain, weight loss, fatigue, and diarrhea. SHP647 is a monoclonal antibody that inhibits a molecule called MAdCAM-1, which is expressed in surface cells from the gastrointestinal tract. This binding blocks the translocation of lymphocytes (the immune system’s cells participate in inflammation) from the bloodstream to the intestine, thereby preventing inflammation. The Phase 2 TURANDOT study (NCT01620255) was a randomized, multicenter, double-blind, placebo-controlled study investigating the safety and efficacy of SHP647 in ulcerative colitis patients. The trial enrolled 357 patients who were assigned to either receive SHP647 in four different doses – 7.5 mg, 22.5 mg, 75 mg, and 225 mg – or a placebo. The study’s primary endpoint was the number of patients achieving disease remission at week 12. Results showed that remission rates at week 12 were higher in patient
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *